Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Mayo Clinic researchers announce promising next generation treatments for multiple myeloma

07.12.2004


The combination of two pills -- thalidomide and dexamethasone -- may be an effective alternative to the intravenous chemotherapy commonly prescribed to patients with multiple myeloma, according to a large collaborative study conducted by the Eastern Cooperative Oncology Group and led by a Mayo Clinic investigator. More than 15,000 Americans are diagnosed annually with multiple myeloma, an incurable cancer of the bone marrow.



Mayo Clinic researchers announced their findings today during a press conference at the annual meeting of the American Society of Hematology in San Diego. They also announced a second new finding: results of a smaller study using a less toxic and more effective "cousin" to thalidomide that they believe will soon assume a leading role in the treatment of myeloma.

The fact that thalidomide -- an old drug with a tragic past of causing birth defects -- can slow the progression of recurrent multiple myeloma is not new. But the studies discussed today show that thalidomide and its analog can be effectively combined with dexamethasone as the initial treatment for patients newly diagnosed with multiple myeloma.


"These oral regimens are as effective as the standard intravenous chemotherapy treatments commonly used as initial therapy for myeloma," says Vincent Rajkumar, M.D., the Mayo Clinic hematologist/oncologist who led the studies. "However, the treatment of multiple myeloma is like a marathon. In addition to improving the initial therapy to get the disease under control, we need to improve other phases of treatment which include stem cell transplantation, maintenance therapy and treatment of relapse. At Mayo, we are committed to improving all phases of treatment, and at the same time, we are striving to develop a cure."

Major findings of the two studies

In the first study, 207 patients newly diagnosed with myeloma were treated. Half were randomly assigned to the combination regimen of thalidomide and dexamethasone. The other half were assigned to take dexamethasone alone as the first treatment for their disease. After four months, a significantly greater proportion of patients -- 63 percent -- responded to the combination of thalidomide plus dexamethasone compared to the 41 percent whose cancer responded to dexamethasone alone.

While these results are encouraging, the side effects of thalidomide plus dexamethasone were significantly higher compared to dexamethasone alone, particularly blood clots. Blood clots occurred in about 18 percent of patients who took the combination drug regimen, compared to only 3 percent of patients who took dexamethasone alone. The researchers stated that the risks and benefits need to be weighed for each patient in determining what regimen to use for initial therapy. Researchers also recommend patients receive blood thinners to minimize the risk of blood clots when using thalidomide plus dexamethasone.

"Based on this study, thalidomide plus dexamethasone has probably become an appropriate replacement for intravenous vincristine, adriamycin, dexamethasone (VAD) chemotherapy, except for patients with less aggressive disease for whom dexamethasone alone may be adequate," says Dr. Rajkumar.

In the second study, Mayo Clinic researchers showed that using a new "cousin" of thalidomide may be more effective and safer in treating newly diagnosed myeloma. This analog of thalidomide is called CC-5013 (lenalidomide) and is not currently commercially available.

Mayo Clinic began a small, tightly-controlled study in 30 patients who were newly diagnosed with multiple myeloma. Patients were treated with CC-5013 plus dexamethasone. The results of this study were announced for the first time at the San Diego meeting. Out of 30 patients treated, 83 percent responded to this therapy, and -- in dramatic contrast to the thalidomide experience -- no blood clots have been observed so far.

"This regimen appears more effective than the thalidomide-dexamethasone regimen, with fewer side effects, and may in the future replace other regimens including the thalidomide-dexamethasone combination as initial treatment for myeloma," Dr. Rajkumar says.

The Eastern Cooperative Oncology Group has just initiated a large, multicenter trial to study CC-5013 in more than 400 newly diagnosed multiple myeloma patients.

Cathy Stroebel | EurekAlert!
Further information:
http://www.mayo.edu

More articles from Health and Medicine:

nachricht Using fragment-based approaches to discover new antibiotics
21.06.2018 | SLAS (Society for Laboratory Automation and Screening)

nachricht Scientists learn more about how gene linked to autism affects brain
19.06.2018 | Cincinnati Children's Hospital Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Temperature-controlled fiber-optic light source with liquid core

In a recent publication in the renowned journal Optica, scientists of Leibniz-Institute of Photonic Technology (Leibniz IPHT) in Jena showed that they can accurately control the optical properties of liquid-core fiber lasers and therefore their spectral band width by temperature and pressure tuning.

Already last year, the researchers provided experimental proof of a new dynamic of hybrid solitons– temporally and spectrally stationary light waves resulting...

Im Focus: Overdosing on Calcium

Nano crystals impact stem cell fate during bone formation

Scientists from the University of Freiburg and the University of Basel identified a master regulator for bone regeneration. Prasad Shastri, Professor of...

Im Focus: AchemAsia 2019 will take place in Shanghai

Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.

Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...

Im Focus: First real-time test of Li-Fi utilization for the industrial Internet of Things

The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.

Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.

Im Focus: Sharp images with flexible fibers

An international team of scientists has discovered a new way to transfer image information through multimodal fibers with almost no distortion - even if the fiber is bent. The results of the study, to which scientist from the Leibniz-Institute of Photonic Technology Jena (Leibniz IPHT) contributed, were published on 6thJune in the highly-cited journal Physical Review Letters.

Endoscopes allow doctors to see into a patient’s body like through a keyhole. Typically, the images are transmitted via a bundle of several hundreds of optical...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Munich conference on asteroid detection, tracking and defense

13.06.2018 | Event News

2nd International Baltic Earth Conference in Denmark: “The Baltic Sea region in Transition”

08.06.2018 | Event News

ISEKI_Food 2018: Conference with Holistic View of Food Production

05.06.2018 | Event News

 
Latest News

Graphene assembled film shows higher thermal conductivity than graphite film

22.06.2018 | Materials Sciences

Fast rising bedrock below West Antarctica reveals an extremely fluid Earth mantle

22.06.2018 | Earth Sciences

Zebrafish's near 360 degree UV-vision knocks stripes off Google Street View

22.06.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>